Westwood Holdings Group Inc. Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Westwood Holdings Group Inc. lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,024 shares of the biopharmaceutical company’s stock after selling 90 shares during the period. Westwood Holdings Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $8,565,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of REGN. Merit Financial Group LLC boosted its position in shares of Regeneron Pharmaceuticals by 8.9% during the fourth quarter. Merit Financial Group LLC now owns 868 shares of the biopharmaceutical company’s stock valued at $618,000 after buying an additional 71 shares during the period. HB Wealth Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 8.2% during the fourth quarter. HB Wealth Management LLC now owns 2,129 shares of the biopharmaceutical company’s stock valued at $1,516,000 after acquiring an additional 161 shares in the last quarter. Diversify Advisory Services LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $234,000. Mechanics Bank Trust Department bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $288,000. Finally, Crossmark Global Holdings Inc. raised its stake in shares of Regeneron Pharmaceuticals by 3.6% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,654 shares of the biopharmaceutical company’s stock valued at $1,890,000 after acquiring an additional 92 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on REGN. Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $865.00 to $800.00 and set an “outperform” rating for the company in a research note on Wednesday, April 30th. Bank of America reduced their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research note on Thursday, April 17th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. Finally, Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $890.60.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $614.79 on Wednesday. Regeneron Pharmaceuticals, Inc. has a one year low of $520.50 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a 50 day moving average price of $596.79 and a 200 day moving average price of $679.72. The firm has a market capitalization of $66.38 billion, a price-to-earnings ratio of 16.06, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the previous year, the company earned $9.55 EPS. Regeneron Pharmaceuticals’s revenue was down 3.7% on a year-over-year basis. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.